39 research outputs found
Budapest-Róma, a hidegháborútól az enyhülésig (könyvismertető)
A recenzált mű: PANKOVITS József: Fejezetek a magyar–olasz politikai kapcsolatok történetéből (1956–1977). Gondolat Kiadó, Budapest, 2005. 164 p
Selection criteria for preoperative endoscopic retrograde cholangiopancreatography before laparoscopic cholecystectomy and endoscopic treatment of bile duct stones. Results of a retrospective; single center study between 1996-2002
AIM: The optimal treatment for bile duct stones (in terms of cost, complications and accuracy) is unclear. The aim of our study was to determine the predictive factors for preoperative endoscopic retrograde cholangiopancreatography (ERCP).
METHODS: Patients undergoing preoperative ERCP (= 8 mm) and/or stone at US examination, coexisting acute pancreatitis and/or acute pancreatitis or jaundice in patient's history. Suspected prognostic factors and the combination of factors were compared to the result of ERCP.
RESULTS: Two hundred and six preoperative ERCPs were performed during the observed period. The rate of successful cannulation for ERC was (97.1%). Bile duct stones were detected in 81 patients (39.3%), and successfully removed in 79 (97.5%). The number of prognostic factors correlated with the presence of bile duct stones. The positive predictive value for one prognostic factor was 1.2%, for two 43%, for three 72.5%, for four or more 91.4%.
CONCLUSION: Based on our data preoperative ERCP is highly recommended in patients with three or more positive factors (high risk patients). In contrast, ERCP is not indicated in patients with zero or one factor (low risk patients). Preoperative ERCP should be offered to patients with two positive factors (moderate risk patients), however the practice should also be based on the local conditions (e.g. skill of the endoscopist, other diagnostic tools)
Egészségügyi szakmai irányelv – A thromboticus thrombocytopeniás purpura (TTP) és a haemolyticus uraemiás syndroma (HUS) kezeléséről
Egészségügyi szakmai irányelv – A thromboticus thrombocytopeniás purpura (TTP) és a haemolyticus uraemiás syndroma (HUS) kezeléséről
Alpha-Melanocyte Stimulating Hormone Protects Against Cytokine-Induced Barrier Damage in Caco-2 Intestinal Epithelial Monolayers
Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies
Pentraxin-3 (PTX3) and C-reactive protein (CRP) have been shown to regulate complement activation in vitro, but their role has not been investigated in complement consumption in vivo. Thrombotic microangiopathies (TMA) are often accompanied by complement overactivation and consumption, therefore we analyzed the relation of the systemic pentraxin levels to the complement profile, laboratory parameters and clinical outcome of TMA patients. We determined the PTX3 and CRP levels, complement factor and activation product concentrations in blood samples of 171 subjects with the diagnosis of typical hemolytic uremic syndrome (STEC-HUS) (N = 34), atypical HUS (aHUS) (N = 44), secondary TMA (N = 63), thrombotic thrombocytopenic purpura (TTP) (N = 30) and 69 age-matched healthy individuals. Clinical data, blood count and chemistry were collected from medical records. To determine the in vitro effect of PTX3 on alternative pathway (AP) activation, sheep red blood cell-based hemolytic assay and AP activity ELISA were used. We found that PTX3 levels were elevated in the acute phase of STEC-HUS, aHUS and secondary TMA, whereas PTX3 elevation was exceptional is TTP. Conversely, a significantly higher median CRP was present in all patient groups compared to controls. PTX3, but not CRP was associated with signs of complement consumption in vivo, and PTX3 significantly decreased the AP hemolytic activity in vitro. Our results provide a detailed description of acute phase-TMA patients' complement profile linked to changes in the systemic pentraxin levels that may support further molecular studies on the function of PTX3 in disease pathogenesis and add to the laboratory assessment of complement consumption in TMA
Korszakváltás a gyermekkori szerzett csontvelő-elégtelenséggel járó kórképek kezelésében Magyarországon = Change in paradigm in the treatment of pediatric acquired bone marrow failure syndromes in Hungary
Absztrakt:
Bevezetés: A gyermekkori szerzett csontvelő-elégtelenségek
ritka, kezelés nélkül halálos betegségek. Egységes diagnosztikájukat és
terápiájukat európai munkacsoport felügyeli. A munkacsoport bevezette a
hypocellularis gyermekkori refrakter cytopenia entitást, melyet csökkentett
intenzitású kondicionálással transzplantálva lényegesen jobb túlélési
eredményeket kaptak. Célkitűzés: A protokollhoz csatlakozás
előtt és az azóta eltelt 5 évben kezelt betegek eredményeinek ismertetése.
Módszer: A 2013 és 2017 között eltelt 5 évben a Magyar
Gyermekonkológiai Hálózat 8 központjában 55 gyermeket kezeltünk (súlyos
aplasticus anaemia: 9, myelodysplasticus szindróma: 41, juvenilis myelomonocyter
leukaemia: 5). Súlyos aplasticus anaemiában 7 esetben végeztünk
őssejt-transzplantációt, egy esetben antithymocytaglobulin-kezelést, egy beteg a
diagnózis előtt meghalt. Myelodysplasiában 37 esetben végeztünk
transzplantációt, 4 esetben a szoros megfigyelést választhattuk. E
transzplantációk 54%-a (20 eset) csökkentett intenzitású kondicionálással
történt. A juvenilis myelomonocyter leukaemiában szenvedő 5 betegnél
transzplantáció történt. Eredmények: A diagnózis és a kuratív
kezelés között eltelt idő medián 92 (3–393) nap volt, súlyos aplasticus anaemia
esetén 28 (3–327) nap. Akut graft versus host betegség II–IV. fokozatú
súlyossággal 22,6%, III–IV. fokozatú súlyossággal 6,8%-ban jelentkezett, míg
betegeink 11,2%-a krónikus graft versus host betegségben szenvedett. A súlyos
aplasticus anaemiával kezelt 8 beteg mindegyike teljes remisszióban él (100%). A
myelodysplasia miatt transzplantált betegek becsült túlélése 85,1%, juvenilis
myelomonocyter leukaemiában 75%. A medián követési idő 30,4 (1,1–62,5) hónap
volt. Jelen eredményeinket összevetettük az 1992 és 2012 között kezelt betegek
eredményeivel. A túlélés az új szemlélet nyomán jelentősen javult, súlyos
aplasticus anaemiában trendszerűen 70%-ról 100%-ra (p = 0,133),
myelodysplasticus szindrómában szignifikánsan 31,3%-ról 85,1%-ra (p = 0,000026).
Következtetés: Paradigmaváltás történt a gyermekkori
szerzett csontvelő-elégtelenségek kezelésében, a betegcsoport túlélése
szignifikánsan növekedett. Orv Hetil. 2018; 159(42): 1710–1719.
|
Abstract:
Introduction: Acquired bone marrow failures are rare but fatal
diseases in childhood. Since 2013, Hungary has been participating as a full
member in the work of the European Working Group on uniform diagnostics and
therapy in patients with acquired bone marrow failure syndromes. Hypocellular
refractory cytopenia of childhood has been emphasized as a frequent entity,
transplanted by reduced intensity conditioning with excellent outcomes.
Aim: To analyse and compare the results of treatment before
and after our joining. Method: A total of 55 patients have been
treated in the 8 centres of the Hungarian Pediatric Oncology Network during 5
years between 2013 and 2017 (severe aplastic anemia: 9, myelodysplastic
syndrome: 41, juvenile myelomonocytic leukemia: 5 patients). Allogeneic
hematopoietic stem cell transplantation was performed in severe aplastic anemia
in 7 cases, while antithymocyte globulin was administered in one case and one
patient died before diagnosis. In patients with myelodysplastic syndromes, watch
and wait strategy was applied in 4, while transplantation in 37 cases. Reduced
intensity conditioning was used in 54 percent of these cases. Transplantation
was the treatment of choice in all 5 patients with juvenile myelomonocytic
leukemia. Results: In the whole patient cohort, the time from
diagnosis to treatment was median 92 (3–393) days, while in severe aplastic
anemia median 28 (3–327) days only. Grade II–IV acute graft versus host disease
occurred in 22.6%, grade III–IV in 6.8% and chronic in 11.2%. All the patients
treated with severe aplastic anemia are alive and in complete remission (100%).
The overall estimated survival rate is 85.1% in myelodysplastic syndrome, while
75% in juvenile myelomonocytic leukemia. The median follow-up was 30.4
(1.1–62.5) months. There was a remarkable increase in overall survival comparing
the data before (1992–2012) and after (2013) joining the international group,
70% vs. 100% (p = 0.133) in severe aplastic anemia and 31.3% vs. 85.1% (p =
0.000026) in myelodysplastic syndrome. Conclusion: Due to a
change in the paradigm of the conditioning regimen in hypocellular refractory
cytopenia of childhood, the overall survival rate has significantly increased.
Orv Hetil. 2018; 159(42): 1710–1719
Elevated plasma neutrophil elastase concentration is associated with disease activity in patients with thrombotic thrombocytopenic purpura.
INTRODUCTION: Genetic and autoimmune risk factors contribute to the development of thrombotic thrombocytopenic purpura (TTP) but triggers are needed to bring about acute disease. The aim of the study was to investigate the association of neutrophil activation with acute TTP, to assess whether neutrophil activation changes during plasma exchange therapy and to show if complement- and neutrophil activation are parallel, characteristic processes in acute TTP. MATERIALS AND METHODS: Altogether 49 EDTA-plasma samples of 21 TTP patients with acute disease and 17 in remission were investigated along with 20 healthy controls. A stable complex of PMNE-proteinase-inhibitor was measured by ELISA (Calbiochem, Merck-Millipore, Darmstadt, Germany). RESULTS: Acute disease was associated with significantly increased PMNE levels, the group medians were similarly low in TTP patients in remission and in healthy controls. Increased PMNE levels were characteristic for hematologically active and ADAMTS13 deficient form of TTP. PMNE concentration inversely correlated to disease activity markers platelet count (r=-0.349, p=0.032) and hemoglobin levels (p=-0.382 p=0.018). Achievement of remission was associated with significant reduction of plasma PMNE levels (p=0.031, Wilcoxon test). There was positive correlation between PMNE levels and complement activation markers C3a and Bb. CONCLUSIONS: We report increased PMNE levels in acute TTP and showed its association to activity markers of acute TTP and complement activation. Effective treatment of an acute TTP episode resulted in marked decrease in PMNE levels. Our data support and extend previous observations that neutrophil extracellular traps may be released in acute TTP and potentially contribute to the pathophysiology of this disease